New System Takes Legwork Out of Tracing Fake Drugs (China)
This article was originally published in PharmAsia News
Executive Summary
The Shanghai FDA will increase its scrutiny of the circulation of pharmaceutical drugs as the second phase of its trading supervision system gets underway. The system supervises drugs and vaccines purchased by the city's disease control center, hospitals, and general drug stores. The Shanghai FDA will trace the entire batch of medicine immediately if any accidents occur involving adverse drug reactions or counterfeit medicines. All 128 drug wholesale companies in Shanghai must report each purchase and sale, including product details such as where it was purchased and whom it was sold to. The supervision system was launched earlier this year, when the Shanghai FDA successfully traced the origin of an immunoglobulin injection produced by the Baiyi Pharmaceutical Company from Guangdong Province within just 10 minutes after receiving notification about a safety problem. (Click here for more - May Require Free Registration
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.